MannKind | MNKD - Loan Capital


MannKind reported $548.44M in Loan Capital for its fiscal quarter ending in December of 2025.





Loan Capital Change Date
Adma Biologics USD 70.08M 3.32M Sep/2025
BioCryst Pharmaceuticals USD 194.37M 48.43M Sep/2025
Eli Lilly USD 40.87B 5.6M Dec/2025
Halozyme Therapeutics USD 2.14B 1.34B Dec/2025
Insmed USD 540.96M 1.24M Dec/2025
Karyopharm Therapeutics USD -0.93 0.67 Dec/2024
MacroGenics USD 70.26M 4K Sep/2025
MannKind USD 548.44M 244.79M Dec/2025
Merck USD 39.97B 6B Sep/2025
Minerva Neurosciences USD 0 86.58M Sep/2024
Novavax USD 223.63M 187K Sep/2024
Novo Nordisk DKK 14.02B 224.49M Sep/2025
Pfizer USD 57.41B 93M Sep/2025
Sanofi EUR 15.72B 2.45B Dec/2025
Xencor USD 76.48M 11.29M Dec/2025